Newsroom

  • December 20, 2019
    Oncorus Appoints Mary Kay Fenton to its Board of Directors

    — Announces additional $10 million in Series B financing, bringing total round gross proceeds to $89.6 million — CAMBRIDGE, Mass., Dec. 20, 2019 – Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has appointed Mary Kay Fenton to its Board of Directors. Ms. […]

    Learn More
  • October 22, 2019
    John McCabe Joins Oncorus, Inc. as Chief Financial Officer

    –Seasoned industry finance executive to help guide Oncorus as it advances toward the clinic and progresses next-generation viral immunotherapies– Cambridge, Mass.; October 22, 2019—Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of John McCabe as Chief Financial Officer (CFO). Prior to joining Oncorus, […]

    Learn More
  • August 21, 2019
    Oncorus Announces $79.5 Million Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors

    –Company advancing broad pipeline of next-generation oncolytic virus therapies for both Intratumoral and intravenous administration for multiple solid tumor indications– –Novel innovations to enhance potency and safety enable best-in-class potential– Cambridge, MA, August 21, 2019 – Oncorus, Inc., an oncolytic virus company focused on driving innovation to transform outcomes for cancer patients, today announced the […]

    Learn More
  • May 16, 2019
    Oncorus to Present at Upcoming Healthcare Investor Conferences

    Oncorus to Present at Upcoming Healthcare Investor Conferences CAMBRIDGE, Mass., May 16, 2019 – Oncorus, Inc., an oncolytic virus therapeutics company focused on driving innovation to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Ted Ashburn, M.D., Ph.D., will provide a company overview and pipeline update at the following […]

    Learn More
  • April 9, 2019
    AACR Annual Meeting 2019 Presentations

    Oncorus had four abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019, which took place from March 29 through April 3, 2019 in Atlanta, GA. Oral Presentation – ONCR-177 Preclinical Data Preclinical data supporting the clinical advancement of our lead clinical candidate, ONCR-177, were featured in an oral presentation the […]

    Learn More
  • April 1, 2019
    Oncorus Presents Preclinical Data Supporting the Advancement of its Lead Oncolytic Virus Therapy Clinical Candidate, ONCR-177

    Oncorus Presents Preclinical Data Supporting the Advancement of its Lead Oncolytic Virus Therapy Clinical Candidate, ONCR-177 — Intra-tumoral administration in multiple preclinical tumor models results in high partial and complete response rates on both injected and non-injected tumors — — Five-transgenes potently stimulate systemic anti-tumor immunity; novel miR attenuation strategy allows for selective oncolysis of […]

    Learn More

Media Inquiries: media@oncorus.com

Top